المؤلفون: Shen, Xinyang¹ (AUTHOR), Ma, Yuan^2,3 (AUTHOR) mayuan@hkbu.edu.hk, Luo, Hang² (AUTHOR), Abdullah, Razack³ (AUTHOR), Pan, Yufei³ (AUTHOR), Zhang, Yihao² (AUTHOR), Zhong, Chuanxin³ (AUTHOR), Zhang, Baoting² (AUTHOR) zhangbaoting@cuhk.edu.hk, Zhang, Ge³ (AUTHOR) zhangbaoting@cuhk.edu.hk

المصدر: Pharmaceutics. Jan2025, Vol. 17 Issue 1, p40. 23p.

مصطلحات موضوعية: *PEPTIDES, *PACLITAXEL, *CANCER treatment, *TREATMENT effectiveness, *IMMUNE response, *CANCER cells, *APTAMERS

المؤلفون: Escrich Montañana, Ainoa

المساهمون: University/Department: Universitat Pompeu Fabra. Departament de Medicina i Ciències de la Vida

Thesis Advisors: Moyano Claramunt, Elisabet, Sánchez Muñoz, Raúl

المصدر: TDX (Tesis Doctorals en Xarxa)

مصطلحات موضوعية: Biotechnological production, Gene regulation, Paclitaxel, Taxane biosynthesis, Taxus spp., Biosíntesis de taxanos, Producción biotecnológica, Regulación genética

وصف الملف: application/pdf

URL الوصول: http://hdl.handle.net/10803/687277

المؤلفون: Ji, Yating¹ (AUTHOR), Hao, Junxu¹ (AUTHOR), Tao, Xu¹ (AUTHOR), Li, Zhihang¹ (AUTHOR), Chen, Lijiang¹ (AUTHOR) clj1172023@163.com, Qu, Na¹ (AUTHOR) quna@lnu.edu.cn

المصدر: Pharmaceutical Development & Technology. Jul2024, Vol. 29 Issue 6, p627-638. 12p.

مصطلحات موضوعية: PACLITAXEL, ANTINEOPLASTIC agents, EXTRACELLULAR vesicles, NANOPARTICLES, ZETA potential, BIOFILMS

المؤلفون: Merck Sharp & Dohme LLC, Foundation Medicine, Go-2 Lung

المصدر: Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab With or Without Chemotherapy in Black Patients With NSCLC

المصدر: A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Sands JM, Mandrekar SJ, Kozono D, Oxnard GR, Hillman SL, Wigle DA, Govindan R, Carlisle J, Gray J, Salama JK, Raez L, Ganti A, Foster N, Malik S, Bradley J, Kelly K, Ramalingam SS, Stinchcombe TE. Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy. 2021 Jun;13(9):727-734. doi: 10.2217/imt-2021-0019. Epub 2021 Apr 21.

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Rayego-Mateos S, Morgado-Pascual JL, Lavoz C, Rodrigues-Diez RR, Marquez-Exposito L, Tejera-Munoz A, Tejedor-Santamaria L, Rubio-Soto I, Marchant V, Ruiz-Ortega M. CCN2 Binds to Tubular Epithelial Cells in the Kidney. Biomolecules. 2022 Feb 3;12(2):252. doi: 10.3390/biom12020252.

المصدر: Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

المصدر: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Kehl KL, Zahrieh D, Yang P, Hillman SL, Tan AD, Sands JM, Oxnard GR, Gillaspie EA, Wigle D, Malik S, Stinchcombe TE, Ramalingam SS, Kelly K, Govindan R, Mandrekar SJ, Osarogiagbon RU, Kozono D. Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). JAMA Oncol. 2022 May 1;8(5):717-728. doi: 10.1001/jamaoncol.2022.0039.

المصدر: Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With PTEN/AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

Other URLs: https://grants.nih.gov/policy/sharing.htm

المؤلفون: NRG Oncology

المصدر: Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study

Other URLs: https://grants.nih.gov/policy/sharing.htm

المؤلفون: Merck Sharp & Dohme LLC

المصدر: A Phase 1/2, Open-Label, Dose Escalation and Expansion Study with Spevatamig (PT886) Followed by a Multi-cohorT Study in Patients with Advanced GastrIc, Gastroesophageal JuNction (GEJ), or Pancreatic Ductal AdEnocarcinomas of Spevatamig (PT886), in Combination with Either ChemotherApy, And/or the ChecKpoint Inhibitor Pembrolizumab. the TWINPEAK Study

المصدر: A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer

Other URLs: http://engagezone.msd.com/ds_documentation.php

المصدر: Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer

Other URLs: https://grants.nih.gov/policy/sharing.htm

المساهمون: LIN YANG, Prof

المصدر: Randomized Phase II Clinical Study of Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer

المؤلفون: National Cancer Institute (NCI)

المساهمون: Manali Bhave, Principal Investigator

المصدر: A Phase II Study of High Dose Radiotherapy in Combination with Pembrolizumab Plus Chemotherapy in Patients with PD-L1 Positive Metastatic Triple Negative Breast Cancer